Home/Pipeline/Novel oncology agents

Novel oncology agents

Oncology

Phase 1/Phase 2Active

Key Facts

Indication

Oncology

Phase

Phase 1/Phase 2

Status

Active

Company

R-Pharm

About R-Pharm

R-Pharm is a major, fully-integrated Russian pharmaceutical player with a strategic focus on localizing advanced drug production and developing innovative therapies. The company leverages extensive partnerships with global biopharma leaders to in-license and co-develop products for the Russian and CIS markets, while also advancing its own R&D pipeline. Its significant manufacturing capabilities and government contracts position it as a key domestic supplier, particularly in oncology and critical care. The company's strategy is heavily aligned with Russia's national pharmaceutical import substitution policies.

View full company profile

Therapeutic Areas

Oncology Infectious Disease Cardiovascular Rare Diseases Transplantology

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active